文献速递甲状腺疾病

甲亢病程长及治疗不充分与心血管风险增加相关

Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk.
PubMed 文献 · Thyroid · 2019-02-13

该研究为丹麦Funen县人群队列中的巢式病例对照研究,纳入275,467名至少测过一次血清TSH的个体。结果显示未治疗甲亢患者心血管事件风险升高(OR=1.25,95%CI 1.06-1.48,p=0.007),治疗者未见升高;TSH降低每持续6个月,治疗与未治疗者心血管风险均增加。

要点

  • 未治疗甲亢患者心血管事件风险升高,治疗者未见显著升高。
  • TSH降低每持续6个月,心血管事件风险约增加9%-10%。
  • 提示治疗不充分同样驱动心血管风险,需及时治疗与密切监测。

核心结论

  • 未治疗甲亢患者心血管疾病风险增加,TSH降低持续时间与治疗及未治疗甲亢患者心血管结局风险升高相关,提示风险不仅源于缺乏治疗也源于治疗不充分。

研究设计与样本

  • 丹麦Funen县1995至2011年人群队列中的巢式病例对照研究,纳入275,467名至少有一次血清TSH测量者。
  • 甲亢定义为六个月内至少两次血清TSH降低且间隔至少14天。
  • 心血管疾病事件与对照匹配,采用条件logistic回归计算OR并校正既往合并症。

主要发现

  • 20,651人发生心血管事件,发生率9.5%,为13.2/1000人年(CI 13.0-13.4)。
  • 未治疗甲亢患者心血管风险升高(OR=1.25,CI 1.06-1.48,p=0.007),治疗者未见升高(OR=1.04,CI 0.90-1.22,p=0.57)。
  • TSH降低每6个月,治疗者心血管事件OR=1.09(CI 1.05-1.14,p<0.001),未治疗者OR=1.10(CI 1.05-1.15,p<0.001)。

临床怎么用

  • 对甲亢患者应及早治疗并密切监测甲状腺功能,以减少心血管事件风险。
  • 评估甲亢患者心血管风险时应关注TSH降低的累计持续时间。
  • 治疗中需警惕治疗不充分带来的残余心血管风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cardiovascular disease remains the most prevalent cause of death in hyperthyroidism. However, the impact on cardiovascular events of varying thyroid status and of treatment remains unclarified. The aims of this study were to investigate the association between hyperthyroidism and cardiovascular events in treated and untreated hyperthyroid individuals, as well as exploring the impact of cumulative periods of hyperthyroidism as a proxy for undertreatment on cardiovascular events. METHOD: This was a case-control study nested within a population-based cohort of individuals attending health services in Funen County, Denmark, in the period from 1995 to 2011. Data on comorbidities and mortality were collected from The Danish National Patient Register and The Danish Register of Causes of Death. Participants were 275,467 individuals with at least one serum thyrotropin (TSH) measurement in the study period. Hyperthyroidism was defined as at least two measurements of decreased serum TSH within six months, separated by at least 14 days. Incident cases of cardiovascular disease (myocardial infarction, atrial fibrillation, heart failure, stroke, and cardiovascular death) were matched with controls. Conditional logistic regression analyses were performed to calculate odds ratios (OR) for exposure to hyperthyroidism, adjusting for preexisting comorbidities. RESULTS: A total of 20,651 individuals experienced a cardiovascular event (9.5% incidence rate 13.2/1000 person-years [confidence interval (CI) 13.0-13.4]) compared to euthyroid individuals, conditional logistic regression showed increased cardiovascular risk in untreated hyperthyroid patients (OR = 1.25 [CI 1.06-1.48], p = 0.007) but not in treated hyperthyroid patients (OR = 1.04 [CI 0.90-1.22], p = 0.57)]. The OR for cardiovascular events per six months of decreased TSH was 1.09 ([CI 1.05-1.14], p < 0.001) in treated hyperthyroid individuals, and 1.10 ([CI 1.05-1.15], p < 0.001) in untreated hyperthyroid individuals. CONCLUSIONS: The risk of cardiovascular disease was found to be increased in untreated hyperthyroid patients, and the duration of decreased TSH associated with increasing risk of cardiovascular outcomes in both treated and untreated hyperthyroid individuals. This suggests that increased cardiovascular risk is driven not only by lack of treatment but also by insufficient therapy. The results support timely treatment and careful monitoring of hyperthyroid patients in order to reduce cardiovascular risk.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, et al. Duration of Hyperthyroidism and Lack of Sufficient Treatment Are Associated with Increased Cardiovascular Risk. Thyroid. 2019. PMID: 30648498. doi:10.1089/thy.2018.0320

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。